By mid-2026, the industry has officially entered the era of "Biomarker-Driven Precision." This year, the focus is on the record-breaking success of Zanidatamab and Trastuzumab deruxtecan for treating HER2-positive gallbladder tumors. This innovation is a primary driver for the market, as these targeted agents allow patients with specific genetic "tags" to bypass the harsh side effects of...
English
Arabic
French
Spanish
Portuguese
Deutsch
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek